Onvansertib能够克服Zytiga耐药性并为mCRPC患者提供临床益处

2020-02-14 Allan MedSci原创

Trovagene是一家临床阶段的肿瘤治疗公司,其研究性新药Onvansertib预期用于治疗包括前列腺癌、结肠直肠癌和白血病在内的多种癌症,该公司近日宣布,正在进行的Onvansertib与Zytiga联合治疗转移性去势抵抗性前列腺癌(mCRPC)的II期试验取得了积极结果。

Trovagene是一家临床阶段的肿瘤治疗公司,其研究性新药Onvansertib预期用于治疗包括前列腺癌、结肠直肠癌白血病在内的多种癌症,该公司近日宣布,正在进行的OnvansertibZytiga联合治疗转移性去势抵抗性前列腺癌(mCRPC)的II期试验取得了积极结果。这些数据将在2020ASCO泌尿生殖系统癌症研讨会上公布。

Onvansertib解决了雄激素受体(AR)抗性机制中的耐药问题。在AR改变的患者中,在Zytiga®中添加Onvansertib可使PSA水平降低86%。前列腺癌是出自前列腺的恶性肿瘤。大多数前列腺癌生长速度较为缓慢,但仍有些生长相对快速。癌细胞可转移到骨头和淋巴结等部位。前列腺癌早期可能没有症状,晚期可导致排尿困难、尿血、背痛、骨盆疼痛等症状。转移性去势抵抗性前列腺癌是美国男性癌症第二大死亡原因,许多患者迫切需要新的治疗选择。


原始出处:

https://www.firstwordpharma.com/node/1700571

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1269618, encodeId=51501269618aa, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466231, encodeId=417914662317f, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19113, encryptionId=56fb19113a3, topicName=Zytiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82186780852, createdName=lqrandywkz, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503940, encodeId=69c215039403c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555939, encodeId=fe1f1555939c9, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11397, encryptionId=641e1139ea8, topicName=mCRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d48314676153, createdName=liuquanmn, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569857, encodeId=41c9156985e3b, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
    2020-02-16 rebeccajiejie
  2. [GetPortalCommentsPageByObjectIdResponse(id=1269618, encodeId=51501269618aa, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466231, encodeId=417914662317f, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19113, encryptionId=56fb19113a3, topicName=Zytiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82186780852, createdName=lqrandywkz, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503940, encodeId=69c215039403c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555939, encodeId=fe1f1555939c9, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11397, encryptionId=641e1139ea8, topicName=mCRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d48314676153, createdName=liuquanmn, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569857, encodeId=41c9156985e3b, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
    2020-02-16 lqrandywkz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1269618, encodeId=51501269618aa, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466231, encodeId=417914662317f, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19113, encryptionId=56fb19113a3, topicName=Zytiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82186780852, createdName=lqrandywkz, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503940, encodeId=69c215039403c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555939, encodeId=fe1f1555939c9, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11397, encryptionId=641e1139ea8, topicName=mCRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d48314676153, createdName=liuquanmn, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569857, encodeId=41c9156985e3b, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
    2020-02-16 yibei
  4. [GetPortalCommentsPageByObjectIdResponse(id=1269618, encodeId=51501269618aa, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466231, encodeId=417914662317f, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19113, encryptionId=56fb19113a3, topicName=Zytiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82186780852, createdName=lqrandywkz, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503940, encodeId=69c215039403c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555939, encodeId=fe1f1555939c9, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11397, encryptionId=641e1139ea8, topicName=mCRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d48314676153, createdName=liuquanmn, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569857, encodeId=41c9156985e3b, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=)]
    2020-02-16 liuquanmn
  5. [GetPortalCommentsPageByObjectIdResponse(id=1269618, encodeId=51501269618aa, content=<a href='/topic/show?id=ca6952e52f' target=_blank style='color:#2F92EE;'>#CRP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5275, encryptionId=ca6952e52f, topicName=CRP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1cc90, createdName=rebeccajiejie, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466231, encodeId=417914662317f, content=<a href='/topic/show?id=56fb19113a3' target=_blank style='color:#2F92EE;'>#Zytiga#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19113, encryptionId=56fb19113a3, topicName=Zytiga)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82186780852, createdName=lqrandywkz, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503940, encodeId=69c215039403c, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555939, encodeId=fe1f1555939c9, content=<a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11397, encryptionId=641e1139ea8, topicName=mCRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d48314676153, createdName=liuquanmn, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569857, encodeId=41c9156985e3b, content=<a href='/topic/show?id=bc1352e951' target=_blank style='color:#2F92EE;'>#CRPC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5279, encryptionId=bc1352e951, topicName=CRPC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5daa15584462, createdName=flyingeagle82, createdTime=Sun Feb 16 09:58:00 CST 2020, time=2020-02-16, status=1, ipAttribution=)]

相关资讯

杨森前列腺癌新药获FDA扩大适应症批准

强生集团旗下杨森(Janssen)公司近日宣布,FDA已批准了ZYTIGA(醋酸阿比特龙)联合泼尼松(prednisone)治疗转移高危性去势敏感型前列腺癌(CSPC)患者。该批准基于关键3期临床试验LATITUDE的数据。研究发现,在转移高危性CSPC患者中与安慰剂相比,ZYTIGA联合泼尼松将死亡风险降低了38%。

欧盟委员会(EC)扩展了Zytiga的许可证,以治疗早期前列腺癌

Janssen-Cilag International NV(Janssen)宣布,欧盟委员会(EC)已批准扩大Zytiga(醋酸阿比特龙)联合泼尼松/泼尼松龙的现有上市许可,目前的适应症扩大到早期转移性前列腺癌。醋酸阿比特龙联合泼尼松/泼尼松龙现在可以联合雄激素剥夺疗法(ADT)治疗成年男性新诊断的高危转移性激素敏感性前列腺癌(mHSPC)。"前列腺癌是整个欧洲男性最常见的癌症形式,该决定有助于

Trovagene在ASCO-GU会议上介绍了Onvansertib与Zytiga联合治疗mCRPC的II期研究

Trovagene是一家临床阶段肿瘤治疗公司,采用精准医学方法开发白血病、淋巴瘤和实体瘤癌症的治疗药物,Trovagene近日在加利福尼亚州旧金山的Genitourinary Cancer Symposium(ASCO-GU)会议上公布了正在进行的第II阶段研究,该研究评估了Onvansertib与Zytiga(醋酸阿比特龙)联合治疗转移性去势抵抗性前列腺癌(mCRPC)患者的安全性和耐受性。

重磅!强生Zytiga霸主地位不保,安斯泰来前列腺癌药物Xtandi拿下欧美2大市场

安斯泰来(Astellas)和Medivation合作研发的新一代前列腺癌口服药物Xtandi(enzalutamide)监管方面爆出大好消息。继今年9月FDA批准Xtandi用于前列腺癌化疗前治疗,近日欧盟也已批准Xtandi用于化疗前治疗。尽管强生(JNJ)新一代前列腺癌口服药物Zytiga早在2011年4月上市之后一直统治市场,但Xtandi具有单独用药的独特优势,业界预测,在欧美2大主要市